Document is current
Any future updates will be listed below
-
Authors
Yeo, Megan J. R. https://orcid.org/0000-0002-7906-9080
Zhang, Olivia https://orcid.org/0000-0002-4299-1485
Xie, Xiaowen https://orcid.org/0000-0002-9884-1865
Nam, Eunju
Payne, N. Connor https://orcid.org/0000-0001-9513-6194
Gosavi, Pallavi M. https://orcid.org/0000-0002-0486-5787
Kwok, Hui Si https://orcid.org/0000-0002-2858-8876
Iram, Irtiza https://orcid.org/0009-0009-4037-5054
Lee, Ceejay https://orcid.org/0000-0002-4128-9328
Li, Jiaming
Chen, Nicholas J. https://orcid.org/0000-0002-7975-2787
Nguyen, Khanh
Jiang, Hanjie https://orcid.org/0000-0001-6090-4552
Wang, Zhipeng A. https://orcid.org/0000-0002-5693-7359
Lee, Kwangwoon https://orcid.org/0000-0002-2021-5186
Mao, Haibin
Harry, Stefan A.
Barakat, Idris A.
Takahashi, Mariko
Waterbury, Amanda L. https://orcid.org/0000-0002-4473-2866
Barone, Marco https://orcid.org/0000-0001-7184-2940
Mattevi, Andrea https://orcid.org/0000-0002-9523-7128
Carr, Steven A. https://orcid.org/0000-0002-7203-4299
Udeshi, Namrata D. https://orcid.org/0000-0001-5312-1402
Bar-Peled, Liron https://orcid.org/0000-0003-2687-9546
Cole, Philip A. https://orcid.org/0000-0001-6873-7824
Mazitschek, Ralph https://orcid.org/0000-0002-1105-689X
Liau, Brian B. https://orcid.org/0000-0002-2985-462X
Zheng, Ning https://orcid.org/0000-0002-1039-1581
- License Information
-
More Information
Article History
Received: 13 February 2024
Accepted: 17 December 2024
First Online: 12 February 2025
Competing interests
: B.B.L. is a cofounder, shareholder and member of the scientific advisory board of Light Horse Therapeutics. N.Z. is one of the scientific cofounders and a shareholder of SEED Therapeutics. N.Z. serves as a member of the scientific advisory board of Synthex, Molecular Glue Labs and Differentiated Therapeutics with financial interests. R.M. and N.C.P. are listed as inventors on patent applications related to the CoraFluor TR-FRET probes used in this work. P.A.C. is a co-founder of Acylin Therapeutics and a consultant for Abbvie regarding p300 acetyltransferase inhibitors. L.B.-P. is a founder, consultant and holds privately held equity in Scorpion Therapeutics. R.M. is a scientific advisory board member and equity holder of Regenacy Pharmaceuticals. S.A.C. is a member of the scientific advisory boards of Kymera, PTM BioLabs, Seer and PrognomIQ. The other authors declare no competing interests.
